The Philippine Food and Drug Administration has issued FDA Circular No. 2026-0001, a consolidated compilation of amendments to the ASEAN Cosmetic Directive (ACD) adopted across the 40th, 41st, and 42nd ASEAN Cosmetic Committee (ACC) sessions and their related meetings.

Published via the fda.gov.ph portal, the circular gives the Philippine market a single reference instead of three separate per-session amendment sets. Compliance teams placing cosmetic products on the Philippine market now align formulations, labels, and product safety dossiers against one working document rather than reconciling each ACC session's output in sequence.

What does the consolidation cover?

The ASEAN Cosmetic Directive is the bloc's harmonised technical framework governing cosmetic products. Its annexes cover prohibited and restricted substances, positive lists for permitted colourants, preservatives and UV filters, and provisions on labelling and claims. Each ACC session typically delivers revisions to those annexes — modifying substance lists, tightening use conditions, or updating mandatory language.

By binding the outputs of the 40th through 42nd sessions into one instrument, Circular 2026-0001 removes the historical layer-by-layer reconciliation step. Manufacturers, importers, contract labs, and brand owners operating across more than one ASEAN market gain a coherent baseline for dossier maintenance, label audits, and procurement specifications tied to ingredient admissibility.

What do compliance teams need to do now?

Regulatory affairs professionals should obtain the full consolidated annex text from FDA Philippines and reconcile it against existing formulations, safety data sheets, and label artwork in circulation. Any ingredient affected by an amendment issued at one of the three consolidated ACC sessions — a tightened concentration, a reclassification, or a new use restriction — needs cross-checking against in-market product specifications and pending notifications.

Importers and contract manufacturers with active notification records in the Philippines should flag any line items where the consolidated text diverges from what was filed. Product safety documentation should be reviewed for any ingredient sections relying on previously permitted concentrations that the consolidated annex structure may have shifted.

Labelling teams need to audit finished-goods artworks for any mandatory statements, warnings, allergens, or claims language that the consolidated annex text now applies. Even where local label content matched a single earlier ACC session, the binding of three sessions into one instrument can surface cumulative requirements that existing label copy does not capture.

What open questions does the circular raise?

The public release of Circular 2026-0001 does not specify an entry-into-force date, nor does it confirm a transition period for products already on the Philippine market. Industry typically watches such consolidations for either an implementing order from FDA Philippines or explicit grace-period language for redesign of labels and resubmission of notifications.

A second open question is inter-jurisdictional: whether the other ASEAN national regulators publish equivalent consolidations referencing the same 40th through 42nd ACC outputs, or whether they adopt the Philippines circular as the working baseline by reference. Companies managing parallel notifications across the bloc will want that clarification before initiating reformulation or label-redesign cycles.

What should industry watch next?

Two data points will set the operational impact: the publication of an FDA Philippines implementing order specifying cutoff dates for legacy stock and pending notifications, and any parallel consolidations or guidance from other ASEAN national regulators tied to the same ACC sessions. Submissions filed between now and the implementation date may carry different transition handling than post-effective filings, giving regulatory affairs teams a narrow window to align documentation systems with the consolidated annex text.